Skip to main
AARD

AARD Stock Forecast & Price Target

AARD Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 11%
Hold 22%
Sell 11%
Strong Sell 0%

Bulls say

Aardvark Therapeutics is a promising biopharmaceutical company with a strong focus on developing novel treatments for metabolic diseases, particularly targeting the Bitter Taste Receptors for hunger-associated conditions. Their lead product candidate, ARD-101, has already advanced to Phase 3 clinical trials for hyperphagia associated with PWS, showing potential for significant growth in the PWS market. While there are some potential risks to consider, such as efficacy and safety concerns, overall, Aardvark Therapeutics has a solid foundation and growth potential in the biopharmaceutical market.

Bears say

Aardvark Therapeutics is facing significant challenges and risks, with the FDA placing a full clinical hold on their lead compound, ARD-101, due to concerns about cardiac observations. This hold has resulted in the suspension of the Phase 3 HERO trial and requires a new trial to be conducted, putting the company's regulatory approval and potential partnership opportunities in jeopardy. Additionally, the company's cash runway may be limited, as it faces the need for additional clinical development and potential dilution risk. Overall, Aardvark therapeutics is in a precarious position, causing a negative outlook on its stock.

AARD has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 11% recommend Buy, 22% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aardvark Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aardvark Therapeutics Inc (AARD) Forecast

Analysts have given AARD a Buy based on their latest research and market trends.

According to 9 analysts, AARD has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aardvark Therapeutics Inc (AARD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.